臨床婦人科産科74巻3号

2020年04月発行

今月の臨床 徹底解説！ 卵巣がんの最新治療―複雑化する治療を整理する

ここが知りたい最新の治療戦略《再発治療》

プラチナ抵抗性再発に対して推奨されるレジメンは？

著者： 境秀樹¹ 松本光史¹

所属機関： ¹兵庫県立がんセンター腫瘍内科

ページ範囲：P.401 - P.407

文献概要

●プラチナ製剤抵抗性再発では，既治療薬との交差耐性や既治療薬の毒性を考慮して単剤療法を行う．

●化学療法単独に対して，化学療法にベバシズマブを併用することの有効性が示されている．

●プラチナ製剤抵抗性2レジメン目まで延命効果が認められている．

●QOLが低下した状態や，途中中止が懸念される状態では緩和治療に専念したほうがよい可能性が高い．

参考文献

1）I Vergote, et al : Phase 3 randomisedstudy of canfosfamide（Telcyta, TLK286） versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45 : 2324-2332, 2009

2）Felicia Roncolato, et al : ASCO ANNUAL MEETING ‘16

3）Gordon AN, et al : Recurrent epithelial ovarian carcinoma : a randomized phase IIIstudy of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 : 3312-3322, 2001

4）Katsumata N, et al : Phase II clinical trial of pegylated liposomal doxorubicin（JNS002）in Japanese patients with mullerian carcinoma（epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma）having a therapeutic history of platinum-based chemotherapy : a Phase IIStudy of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol : 777-785, 2008

5）Ten Bokkel Huinink W, et al : Long-term survival in a phase III, randomisedstudy of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15 : 100-103, 2004

6）D'Agostino G, et al : Phase IIstudy of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Onco 88 : 266-269, 2003

7）Ferrandina G, et al : Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26 : 890-896, 2008

8）Mutch DG, et al : Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25 : 2811-2818, 2007

9）Kita T, et al : The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 92 : 813-818, 2004

10）Katsumata N, et al : A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer : a Japanese cooperativestudy. Ann Oncol 11 : 1531-1536, 2000

11）Rose PG, et al : Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma : a Gynecologic Oncology Groupstudy. J Clin Oncol 16 : 405-410, 1998

12）Matsumoto K, et al : The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100 : 412-416（Epub）, 2005

13）Pujade-Lauraine E, et al : Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer : The AURELIA open-label randomized phase III trial. J Clin Oncol 32 : 1302-1308, 2014

14）ASCO 2018, Abstract No.5506